FXEmpire
05 Aug 2026, 10:47 UTC · 1h ago
Raised Guidance Lifts Corcept to 52-Week High
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
FXEmpire
05 Aug 2026, 10:47 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Corcept Therapeutics (CORT) raised its 2026 revenue guidance to up to $1.2 billion. — Raised guidance is a strong bullish signal that typically drives stock price appreciation due to improved future earnings expectations.
+0.60CORT's second-quarter 2026 revenue grew 32% year-over-year to $256.1 million with a 22.9% increase in net income. — Strong historical growth and profitability confirm the company's fundamental strength, supporting a higher valuation.
+0.40Estimated earnings per share (EPS) for CORT are expected to increase by 85.4% this year. — Significant projected EPS growth is a primary driver for institutional buying and stock price targets.
+0.40Which stocks this story touches
Continue reading
6 related stories
Search tags
The company reported record revenue, raised guidance, and hit a 52-week high with strong institutional support.
The stock is mentioned as slipping in the Nasdaq 100.
The stock is mentioned as falling in the Nasdaq 100.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
39m ago
